Kanden Investor Day ー OPTAGE Inc. December 8, 2025 Today's Agenda 1 1. Business Overview ・・・・ P. 2 2. Initiatives in Growth Areas ・・・・ P. 10 • Overview of OPTAGE • ICT Market Structure and Our Strategic Focus Areas • Overview by Segment • Performance, KPIs, and CAPEX • IT Infrastructure Landscape in Japan • Initiatives in Growth Areas • Synergies with the Kansai Electric Power Group • Where We Are Heading Toward 2035 Overview of OPTAGE ○ We provide fiber-optic internet, mobile services, and connectivity sol ...

Transaction Overview - Ageas will acquire 100% ownership of AG Insurance from BNP Paribas Fortis for EUR 1.9 billion[4] - The transaction will be financed via an equity placement of 18.5 million shares at EUR 60 per share, totaling EUR 1.11 billion, along with existing cash and financing facilities[4] - The closing is subject to regulatory approval and is expected in Q2 2026[4] Strategic Rationale - The acquisition offers strategic flexibility and strengthens Ageas' position for potential future inorganic growth opportunities[22, 25] - It allows for further leveraging of AG Insurance's distribution, technical, and operational expertise to deepen group synergies[25] - The deal re-confirms the long-term nature of the bancassurance distribution agreement with BNP Paribas Fortis and deepens collaboration on investments[8, 25, 41] Financial Impact - The transaction is expected to deliver an attractive levered Return on Invested Capital (ROIC) of 15-16%[26, 40] - It is projected to increase HFCF (Holding Free Cash Flow) per share by 7-8% by 2027[26, 33] - The acquisition is expected to provide an immediate uplift of EUR 160-175 million from Belgium and EUR 15 million from the Reinsurance segment starting in 2028[33] Partnership with BNP Paribas - BNP Paribas will maintain a significant stake in Ageas, with a shareholding cap of 25%-1[52] - The partnership is governed by a Relationship Agreement with a 5-year duration and automatic renewal[52] - BNP Paribas supports Ageas' future growth as an independent and autonomous group[52] Elevate27 Targets - The transaction leads to an upgrade of Elevate27 financial targets, including an increase in HFCF and shareholder remuneration[26, 53, 59, 60] - The shareholder remuneration is expected to increase by +10%[60] - HFCF is expected to increase by +13%[59]

Conference Call on Helvetia Baloise Pro Forma Financial Information Matthias Henny, Group CFO Helvetia Baloise 8 December 2025 Overview of contents 2 1) Key messages and preliminary remarks 2) Pro Forma Financial Information 3) Outlook and next milestones 4) Appendix Key messages Merger of equals to form Helvetia Baloise completed on 5 December 2025. Previous communication on benefits of the deal, including on cash and dividend capacity uplift, remain valid. Preparation for operational integration well adva ...

Ohio Utica Joint Acquisition December 2025 Ohio Utica Joint Acquisition December 2025 | 1 Ohio Utica Overview | Vertically Integrated Asset with Significant Growth Agreement to acquire 49% interest in high quality Utica Upstream and Midstream asset to be operated by Infinity Natural Resources ("INR") in a joint acquisition. Asset provides substantial growth in both upstream and midstream assets in the core of the Utica. 140/90 MILES OF GATHERING PIPELINES / WATER DELIVERY SYSTEMS $588 MM PURCHASE PRICE(1) O ...

Gonneville Pd-Ni-Cu Project developing a new globally significant critical minerals mine in Western Australia Pre-Feasibility Study 8 Dec 2025 ASX:CHN Cautionary statements and competent person(s) disclosure Authorisation This Presentation has been authorised for release by the Board Disclaimer This Presentation does not provide investment or financial product advice and does not include all available information on Chalice Mining Limited ("Chalice" or "the Company") and should not be used in isolation as a ...

Financial Performance & Guidance - Q3 2025 net product sales grew to $64.1 million, a 65% increase compared to Q3 2024[10, 158] - Rigel increased its 2025 net product sales guidance to $225 million - $230 million, up from $210 million - $220 million[12] - Rigel anticipates 2025 total revenue of ~$285 million to $290 million[162] - Cash, cash equivalents & short-term investments as of September 30, 2025, was $137.1 million compared to $77.3 million as of December 31, 2024[162] Product Performance - TAVALISSE Q3 2025 net product sales reached $44.7 million, a 70% increase compared to Q3 2024[16] - GAVRETO Q3 2025 net product sales reached $11.1 million, a 56% increase compared to Q3 2024[16] - REZLIDHIA Q3 2025 net product sales reached $8.3 million, a 50% increase compared to Q3 2024[16] R289 Clinical Development - In a Phase 1b study in R/R lower-risk MDS, 33% (6/18) of evaluable transfusion-dependent patients receiving ≥500 mg QD achieved RBC-TI >8 weeks[124, 131] - The median duration of RBC-TI was 22.9 weeks (9 - 104.3)[124] Strategic Collaborations - Contract revenues from collaborations were $5.4 million in Q3 2025[158]

Pociredir 20mg Cohort Data Highlights - The 20 mg cohort data raises the bar on Pociredir's best-in-class potential for treating sickle cell disease[14, 17] - At Week 6, the 20 mg cohort (n=12) showed a 99% mean absolute increase in HbF[17] - 58% of patients (7/12) in the 20 mg cohort achieved ≥20% HbF at their latest study visit[17] - In the 20 mg cohort, the six patients who completed the 12-week treatment period achieved >375-fold induction of HbF[17] Clinical Improvements - The study observed a 28% reduction in Lactate Dehydrogenase (LDH) and a 37% reduction in indirect bilirubin, indicating consistent reductions in markers of hemolysis with the 20 mg dose[71, 72] - There was a 31% reduction in Mean Absolute Reticulocyte Count (ARC) and a 22% reduction in Mean Red Cell Distribution Width (RDW-CV) with the 20 mg dose, indicating consistent improvements in red blood cell morphology and erythropoiesis[75] - Mean hemoglobin increased from 73 g/dL to 81 g/dL in the 20 mg cohort[81] - 67% of patients (8/12) reported no vaso-occlusive crises (VOCs) during the 12-week treatment period[86] Safety and Tolerability - Pociredir at 20 mg was generally well-tolerated, with 23% of patients (3/13) reporting treatment-related adverse events[90] - There were no serious treatment-related adverse events in the 20 mg cohort[90]

Acquisition Overview - Virtus Investment Partners will acquire a 56% majority interest in Keystone National Group for $200 million in cash at closing[13] - Up to $170 million in deferred consideration, including earnout payments, may be paid based on future revenue targets[13] - Management will retain a 44% stake, with Virtus increasing ownership to 75% through staged equity purchases in years 3-6[13] Keystone National Group Highlights - Keystone manages $2.5 billion in assets under management (AUM) across four core strategies[8, 11] - Keystone's flagship $2.0 billion tender offer fund (KPIF) is available in the RIA market[8, 11] - Keystone has invested over $6 billion of capital in more than 750 transactions since its founding in 2006[11] - Keystone's Real Estate Private Credit AUM is ~$400 million and Real Estate Equity AUM is ~$100 million[12] Financial Impact - The transaction is expected to increase Virtus' operating margin by approximately 200 basis points[13] - The estimated contribution to 2026 EPS, as adjusted, is approximately $1.50[13] - Intangible assets are expected to create annual tax savings of approximately $5 million per year[13] Market Context - Non-bank financing represents $1.9 trillion of the ~$5.5 trillion US Specialty Finance market[20] - Private credit accounts for $200-300 billion of the Specialty Finance market[20]

Financial Performance (3Q 2025) - Revenues reached $96.9 million[10], with an operating income of $30.6 million[10] and a net income of $15.1 million[10] - Adjusted EBITDA stood at $61.6 million[10] - A cash distribution of $0.026 per common unit was paid in November 2025[10, 18] Key Transactions & Refinancing - Daqing Knutsen was purchased for a net cash cost of $24.8 million[12], with KNOT guaranteeing the hire rate until July 2032[12, 22] - A common unit buyback program was concluded in October, with 384,739 common units purchased for $3.03 million, averaging $7.87 per unit[13, 28] - The Synnøve Knutsen loan was refinanced with a new $71.1 million senior secured term loan facility[24] - Refinancing of the Tove Knutsen was completed, generating $32 million of net proceeds[16] Contractual Agreements & Fleet Utilization - Fleet operated with 99.9% utilization, or 96.5% overall including the drydocking of the Tove Knutsen[10, 74] - The term of the current time charter for the Bodil Knutsen was extended to a fixed term ending in March 2029, followed by two charterer's options each of one year[17] - The term of the current time charter for the Hilda Knutsen was extended by 3 months firm (to June 2026) plus a further 9 months at the company's option (to March 2027)[15] - A time charter for the Fortaleza Knutsen was executed with KNOT, to commence Q2 2026 for a fixed period of one year plus two charterer's options each for one additional year[27] Strategic Developments - KNOT made an unsolicited non-binding offer to purchase all publicly held common units of the Partnership for $10 in cash per common unit[9, 25] - Contractual backlog expanded to $939.5 million of fixed contracts averaging 2.6 years, with charterers' options averaging a further 4.2 years[32, 54]

Financial Performance - Q3 2025 - Net sales increased by 9%, driven by growth across Victoria's Secret, PINK, and Beauty[4] - International net sales surged by 34%[4] - Adjusted gross margin improved by 170 basis points to 365%[4,7] - Adjusted operating income reached $0 million, exceeding the guidance of an adjusted operating loss of ($35 million) - ($55 million)[4] - Adjusted EPS was reported at ($027), surpassing the guidance of ($055) - ($075)[6] Financial Performance - Year-to-Date 2025 - Net sales increased by 4% to $42836 million[9] - Operating income increased by 18% to $868 million[9] - Net income attributable to Victoria's Secret & Co increased by 1036% to $125 million[9] - Net income per diluted share attributable to Victoria's Secret & Co increased by 1400% to $015[9] Outlook - The company anticipates full-year net sales to be approximately $645 billion to $648 billion[14] - The company anticipates full-year adjusted operating income to be approximately $350 million to $375 million[14]